Printer Friendly

FOUNTAIN PHARMACEUTICALS ANNOUNCES PLACEMENT OF OCTAZOME(TM) IN BLOOMINGDALE'S

 LARGO, Fla., May 3 /PRNewswire/ -- Fountain Pharmaceuticals, Inc. (NASDAQ: FPHI) announced today that its Octazome(TM) line of creams and lotions will be carried in Bloomingdale's commencing in June. Bloomingdale's initial order of product will approximate $250,000 at retail.
 John C. Walsh, Fountain's president, said, "Placement of the Octazome(TM) line in Bloomingdale's is a major step forward, and together with the scheduled expansion of the line into additional Niemen-Marcus stores, we are well on our way to establishing a franchise in the prestige skin care market."
 He also indicated that Fountain is discussing the placement of the line with two other upscale chains.
 Bloomingdale's will carry Octazome(TM) initially in six locations, including its flagship store in Manhattan, three other New York metropolitan area stores, Boston, Florida, and later in the year in other major markets. The Octazome(TM) promotional program will be supported with a fashion press campaign lead by the Marilyn Evins agency in New York.
 Based in Largo, Fla., Fountain Pharmaceuticals is a publicly traded company that specializes in the application of encapsulated drug delivery systems for the pharmaceutical and cosmetic industries. The company's shares are traded in the NASDAQ small caps grouping.
 -0- 5/3/93
 /CONTACT: John C. Walsh, CEO of Fountain Pharmaceuticals, Inc., 813-392-5300/
 (FPHI)


CO: Fountain Pharmaceuticals, Inc.; Bloomingdale's ST: Florida, New York IN: HOU REA SU:

JB-AW -- FL006 -- 3654 05/03/93 10:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:235
Previous Article:CONSUMERS POWER SERVES RECORD ELECTRIC SENDOUT FOR APRIL
Next Article:SOUTHERN BELL EXPECTS TO PROCESS 85 MILLION MOTHER'S DAY CALLS
Topics:


Related Articles
FOUNTAIN PHARMACEUTICALS SIGNS AGREEMENT WITH BROCADES PHARMA
BARCOLENE/PENN CHAMP AND FOUNTAIN PHARMACEUTICALS TEAM UP FOR EXCITING NEW SUNTAN PROGRAM
FOUNTAIN ANNOUNCES COMPLETION OF MANAGEMENT REORGANIZATION; DR. FOUNTAIN TO REJOIN THE COMPANY
FOUNTAIN ANNOUNCES COMPLETION OF MANAGEMENT REORGANIZATION; DR. FOUNTAIN TO REJOIN THE COMPANY
FOUNTAIN PHARMACEUTICALS, INC. ANNOUNCES REGISTRATION OF RESTRICTED SECURITIES
FOUNTAIN PHARMACEUTICALS PRODUCT SHIPMENTS ANNOUNCED
FOUNTAIN PHARMACEUTICALS ANNOUNCES EXTENSION OF NASDAQ LISTING
Fountain Pharmaceuticals, Inc. Announces The Sale Of $2.5 Million Of Convertible Preferred Stock And Changes In Board Membership
Fountain Pharmaceuticals, Inc. Announces Appointment of New President/CEO.
Fountain Pharmaceuticals, Inc. and Dermik Announce Intentions on Future Collaboration.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters